Introduction
Melanocytes are specialized cells found predominantly in the skin and eyes that form the pigment melanin, a polymer composed of several types of subunits formed from L-3,4-dihydroxyphenylalanine. Melanin is deposited in subcellular particles called melanosomes. Cutaneous melanocytes originate from neural-crest progenitors that migrate to the skin during embryonic development. In the skin, melanocytes reside in the basal layer of the epidermis and are present also in hair follicles. Skin melanocytes form an epidermal unit composed of one melanocyte having long cellular processes and about 30 keratinocytes.
Melanocytes are found also in a benign nevus, a common lesion observed in the skin which is a precursor of malignant melanoma. In the nevus, the melanocytes (called nevocytes) are morphologically different and although nevi are benign and the melanocytes in them are senescent, they may develop, though rarely, into melanoma, a highly malignant tumor whose incidence is rising steadily in western countries. Smaller part of melanoma tumors (approximately 10-15%) occurs in families with hereditary predisposition (Hansson, 2010) . Most familial melanomas harbour germline mutations in the CDKN2A gene encoding the p16INK4 protein, a cdk inhibitor. Much smaller number of hereditary cases has germline mutations resulting in amino acid substitutions in the p14ARF or CDK4 proteins. Sporadic cases of melanoma predominate and can be grouped into four clinical subtypes: acral lentiginous melanoma, nodular melanoma, lentigo maligna and superficial spreading melanoma (SSM), which is by far the most common form of melanoma and develop into vertical-growth phase (VGP) melanoma. Lentigo maligna and SSM are most frequently associated with intermittent UV exposure (Gray-Schopfer et al., 2007).
About 60-70% of melanomas harbour mutations of the B-RAF gene (Davies et al., 2002 ) (in the vast majority the mutation is V600E), while mutations of N-RAS are present in about 10-25% of all tumors. Activating N-RAS and B-RAF mutations demonstrate mutual exclusivity in melanomas. B-RAF mutations are present already in nevus cells, conferring senescence to these cells by a mechanism known as oncogene-induced senescence, possibly explaining the low rate of malignant transformation of nevi. Activation of these two oncogenes triggers the MEK-ERK kinase cascade that is almost invariantly activated in melanomas; however, other signaling pathways can probably activate the cascade. Therefore, small molecule inhibitors of kinases in the pathway are considered as a promising tool for melanoma treatment (Solit et al., 2006; Bogenrieder and Herlyn, 2011) . Although B-RAF inhibitors seem to be rational antimelanoma drugs, resistance occurs in a large proportion of patients, because other stimuli may also activate MAPKs (Alcala and Flaherty, 2012) . Many other genes are deregulated during melanoma progression, mainly antiapoptotic genes and genes which are involved in the invasiveness, migration, and metastasis of melanoma, many of which are regulated by MITF-M (microphthalmia-associated transcription factor), a pivotal transcription factor of the melanocyte lineage ( Figure 1 ). 
Regulation of MITF expresion
MITF gene locus encodes a transcription factor of the basic-helix-loop-helix-leucine zipper (bHLH-LZ) type, belonging to a large family of bHLH factors comprising also for example the myc oncogenes. Together with TFE3, TFEB, and TFEC, MITF-M constitutes a small bHLH subfamily sharing high sequence similarity. MITF gene was identified twenty years ago and cloned from a microphthalmic and hypopigmented mutant mouse having transgene-insertion at the MITF locus (Hodgkinson et al., 1993) . The MITF locus has at least nine promoters producing corresponding MITF isoforms which differ in the first exon and share exons 2-9 (reviewed by Steingrimsson et CREB is an another transcription factor activating MITF-M expression. The αMSH hormone increases cAMP level, therefore activates PKA (protein kinase A) and the consequence is an increased MITF-M expression and pigmentation. Recently, it has been described that TGF-β represses protein kinase A activity and therefore reduces the CREB-dependent transcription of the MITF-M promoter (Pierrat et al., 2012) . CREB requires the coactivators p300/CBP. These proteins, which are histone acetyltransferases, interact with MITF-M and are believed to coactivate at least some MITF-M target genes (Sato et al., 1997; Price et al., 1998). Furthermore, the phosphorylation of serine 73 is required for MITF-M-p300 interaction, at least after the Kit signaling (Hemesath et al., 1998) . Controversially, however, it has been observed that MITF-M with mutation of this serine and the N-terminus truncated (including the S73) MITF-M construct were fully capable of activating promoter-reporter and the endogenous target tyrosinase (Vachtenheim et al., 2007) .
Whereas the role of p300/CBP in coactivating endogenous targets might be disputable, another prominent epigenetic mechanism has been found to be crucial for MITF-M expression. The chromatin remodeling complex SWI/SNF has been found to be essential for the MITF-M expression in melanoma cells . The chromatin remodeling complex SWI/SNF is composed of about 10-12 proteins and exists in the cells as several subcomplexes capable of changing the local structure of chromatin at the promoter sites. It has important functions in expression of various lineage specific genes and plays an essential function in basic cell processes that include mainly regulation of transcription, DNA replication and repair, and homologous recombination. The SWI/SNF is strongly implicated in human cancer, as several SWI/SNF subunits has been reported missing or strongly downregulated in tumors, and numerous experimental findings suggest that this complex functions as a tumor suppressor (reviewed by Reisman et ). Recently, we have found (Ondrušová et al., submitted) that Brg1 knockdown in melanoma cells downregulates also Sox10, an upstream MITF-M regulator, so this mechanism might also contribute to the MITF-M regulation. It is intriguing that for most cancers, SWI/SNF complex is a clear tumor suppressor, whereas a small number of cancer types has been recognized (prostate cancer, gastric and colorectal cancer, and melanoma) for which the SWI/SNF seems to function as a tumor promoter, probably by upregulating genes required for proliferation, antiapoptotic activity, invasivity or other characteristics of cancer cells.
It should be noted that the cut-homeodomain transcription factor Onecut-2 (OC-2) also stimulates MITF-M promoter activity. It binds to its promoter (although no OC-2 binding sites were found in the promoter region) and overexpression of ectopic OC-2 in transfected cells stimulates MITF-M promoter activity. Moreover, OC-2 is expressed in melanocytes (Jacquemin et al., 2001 ). We observed that even cdk inhibitor p21, which itself is a target of MITF-M, is its transcriptional activator (Sestakova et al., 2010) . It probably stimulates the CREB pathway and is widely expressed in melanoma cell lines and tumors, and presumably protects malignant cells against apoptotic stimuli.
The POU domain containing transcription factor Brn-2 (N-Oct-3) has been recognized as a repressor of MITF-M expression in melanoma cells (Goodall et al., 2008) . Brn-2 bound to MITF-M promoter both in gel-shift assays and in chromatin immunoprecipitation, indicating a direct repression. An inverse correlation between Brn-2 and MITF-M expression was found in melanomas and transfection assays showed that expression of exogenous Brn-2 substantially repressed the MITF-M promoter-reporter. Brn-2 also marked the subpopulation of low MITF-M cells in melanomas (which are heterogenous in MITF-M expression) and these cells displayed low proliferation but high invasiveness (also see below).
One of the effectors of the Hedgehog signaling, transcription factor GLI2, which also mediates the effect of the TGF-β/SMAD pathway, is another repressor of MITF-M expression (Javelaud has been implicated in morphogenesis of a wide range of organs including limbs, kidneys, lung, mammary gland, and heart. Tbx2 is expressed in melanoma cell lines in positive correlation with MITF-M. Tbx2 promoter contains a consensus MITF-M recognition element to which MITF-M is recruited and activates Tbx2 expression (Carreira et al., 2000) . As Tbx2 is overexpressed in several cancers including melanoma and plays a role in suppressing senescence, MITF-M modulates the survival of melanoma cells also via this factor.
Downstream targets of MITF
MITF-M also upregulates the expression of clearly antiapoptotic genes. First, it activates the general antiapoptotic protein Bcl-2 (McGill et al., 2002) , which is important for the survival of both melanoma and melanocyte lineage. Second, melanoma inhibitor of apoptosis (ML-IAP, livin) is a potent inhibitor of apoptosis in melanoma and is directly regulated by MITF-M (Dynek et al., 2008) . It was shown that MITF-M was recruited to the ML-IAP promoter by chromatin immunoprecipitation and gel shift assays, activated ML-IAP promoter-reporter, and downregulation of MITF-M abrogated ML-IAP expression. The SLUG protein was reported to be a crucial determinant of melanoma metastasis, and its gene is also upregulated by MITF-M (Gupta et al., 2005) . Another important gene regulated by MITF-M is Dia (DIAPH1, encoding the diaphanous-related formin Dia1). Increased MITF-M level favors expression of Dia and higher proliferation of melanoma cells. On the contrary, lower MITF-M downregulates Dia but the cdk inhibitor p27 is stabilized resulting in slower proliferation but higher invasive potential. Thus, a "rheostat" model is proposed where MITF-M levels determine the proliferation, differentiation, and invasiveness of melanoma cells (Carreira et al., 2006) . Noteworthy, many other genes were identified as potential MITF-M targets, by the microarray analysis (Hoek et al., 2008) . The SWI/SNF complex has been shown to be an important coactivator for many target genes, especially those involved in pigment formation, in human melanoma cell lines (Keenen et al., 2010) . Of the two ATPases of the complex, Brg1 seems to be more important than Brm since its knockdown downregulates the MITF-M target genes more efficiently than Brm knockdown .
MITF-M is considered to be a melanoma oncogene because mutations and amplifications were found in patients´ samples (Garraway and Sellers, 2006; Levy et al., 2006; Cronin et al., 2009) . Copy gains at the MITF locus were found in about 10% melanoma samples and mutations of the MITF-M pathway were also described, even in the Sox10 gene (Cronin et al., 2009) . Recently, novel MITF-M mutation, E318K, has been identified. This mutation is a germline allele variant (Yokoyama et al., 2011) . E318K MITF-M encodes a protein with impaired sumoylation of MITF-M and differential regulation of several MITF-M targets. For example, the mutant enhances MITF-M protein binding to the HIF1α promoter, a MITF-M known target, and increases its transcriptional activity (Bertolotto et al., 2011; Yokoyama et al., 2011) . The presence of this allele constitutes more than fivefold risk factor for melanoma and renal cell carcinoma. Further, the mutant protein enhanced melanocytic and renal cell carcinoma clonogenicity, migration and invasion, further implicating this MITF-M variant as a risk factor for these two cancers (Bertolotto et al., 2011) . Together, as MITF-M is strictly required for the embryonic development of melanocytes, maintains the survival of melanoma, and gene amplifications and mutations in the protein coding region have been found, it is considered as a lineage addiction oncogene.
